약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 1.

Table. 1. Baseline characteristics of all cases and non-cases adverse event reports for GLP-1 RAs and Other antidiabetic drugs in WHO-UMC VigiBase® from April 2005 to January 2023
Characteristics America (N, %) Europe (N, %) Asia (N, %) Other regions (N, %)
Cases Non-cases Cases Non-cases Cases Non-cases Cases Non-cases
No. of reports 454 (0.86) 52,359 (99.14) 241 (1.14) 20,966 (98.86) 56 (1.13) 4,910(98.87) 6(0.82) 723 (99.18)
Age (years)
18-44 60 (13.22) 4,387 (8.38) 42 (17.43) 2,555 (12.19) 4 (7.14) 1,247 (25.40) 4 (66.67) 334 (46.20)
45-64 245 (53.96) 26,634 (50.87) 107 (44.40) 11,067 (52.97) 17 (30.36) 2,277 (46.37) 2 (33.33) 323 (44.67)
65-74 118 (25.99) 15,665 (29.92) 71 (29.46) 5,544 (26.44) 17 (30.36) 696 (14.18) 0 (0.00) 57 (7.88)
≥75 31 (6.83) 5,673 (10.83) 21 (8.71) 1,800 (8.59) 18 (32.14) 690 (14.05) 0 (0.00) 9 (1.24)
Sex
Male 202 (44.49) 21,093 (40.29) 106 (43.98) 9,217 (43.96) 33 (58.93) 2,071 (42.18) 1 (16.67) 230 (31.81)
Female 252 (55.510 31,266 (59.71) 135 (56.02) 11,749 (56.04) 23 (41.07) 2,839 (57.82) 5 (83.33) 493 (68.19)
Report type
Spontaneous 406 (89.43) 51,292 (97.96) 207 (85.89) 17,079 (81.46) 44 (78.57) 2,164 (44.07) 4 (66.67) 533 (73.72)
Report from study 39 (8.59) 685 (1.31) 34 (14.11) 3,878 (18.50) 12 (21.43) 1,298 (26.44) 2 (33.33) 189 (26.14)
Other 1 (0.22) 295 (0.56) 0 (0.00) 9 (0.04) 0 (0.00) 130 (2.65) 0 (0.00) 1 (0.14)
Unknown 8 (1.76) 87 (0.17) 0 (0.00) 0 (0.00) 0 (0.00) 1,918 (26.84) 0 (0.00) 0 (0.00)
Seriousness*
Yes 416 (91.63) 11,193 (21.38) 194 (80.50) 5,955 (28.40) 49 (87.50) 1,302 (26.52) 4 (66.67) 134 (18.53)
No 36 (7.93) 40,731 (77.79,) 46 (19.09) 14,950 (71.31) 5 (8.93) 3,475 (70.77) 1 (16.67) 543 (75.10)
Unknown 2 (0.44) 435 (0.83) 1 (0.41) 61 (0.29) 2 (3.57) 133 (2.71) 1 (16.67) 46 (6.36)
Notifier
Physician 149 (32.82) 4,968 (9.49) 150 (62.24) 10,301 (49.13) 44 (78.57) 2,038 (41.51) 1 (16.67) 213 (29.46)
Pharmacist 7 (1.54) 1,080 (2.06) 16 (6.64) 2,403 (11.46) 1 (1.79) 314 (6.40) 0 (0.00) 48 (6.64)
Others 298 (65.64) 46,311 (88.45) 75 (31.12) 8,262 (39.41) 11 (19.64) 2,558 (52.10) 5 (83.33) 462 (63.90)

*Fatal, Life-threatening, requiring hospitalization, resulting in significant disability/incapacity, and other medically important conditions

Yakhak Hoeji 2024;68:112-20 https://doi.org/10.17480/psk.2024.68.2.112
© 2024 Yakhak Hoeji